Sarah Sammons/medicine.duke.edu
May 9, 2025, 10:15
Sarah Sammons Comments on TDXd Use in Early HER2+ Breast Cancer
Sarah Sammons, Breast Medical Oncologist at the Dana-Farber Cancer Institute, shared a post on X by Erika Hamilton, Medical Oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute, adding:
“I wish this was TCHP x 6 versus TDXd x 6 which would have been more relevant to US practice patterns which already avoid anthracyclines. While TCHP is incredibly toxic and I am eager to replace, if compelling, we will be escalating to 8 neoadj cycles vs 6.”
Quoting Erika Hamilton’s post:
“Another positive trial in breast cancer, TDXd followed by THP beats ddAC-THP in neoadjuvant HER-2+ early breast cancer. We’ve seen a lot of positive TDXd results, but this is the first in the early-stage setting!”
Sarah Sammons responded to recent findings showing the benefit of TDXd followed by THP over ddAC-THP in early HER2-positive breast cancer. She highlighted the need for data aligned with U.S. practice, which typically avoids anthracyclines, and signaled openness to treatment adjustments based on compelling evidence.
More posts featuring Sarah Sammons and Erika Hamilton.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 16, 2025, 17:55
Jul 16, 2025, 17:38
Jul 16, 2025, 17:37
Jul 16, 2025, 17:04
Jul 16, 2025, 16:51
Jul 16, 2025, 16:34
Jul 16, 2025, 16:18